Why did I stop? And why did I restart? Perspectives of women lost to follow-up in option B+ HIV care in Dar es Salaam, Tanzania.
Breastfeeding
HIV-positive women
Loss to follow up
Option B +
Pregnant
Reasons
Tanzania
Journal
BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562
Informations de publication
Date de publication:
27 Aug 2019
27 Aug 2019
Historique:
received:
20
03
2019
accepted:
19
08
2019
entrez:
29
8
2019
pubmed:
29
8
2019
medline:
27
11
2019
Statut:
epublish
Résumé
Despite an increased uptake of option B+ treatment among HIV- positive pregnant and breastfeeding women, retaining these women in care is still a major challenge. Previous studies have identified factors associated with loss to follow-up (LTFU) in HIV care, however, the perspectives from HIV-positive pregnant and breastfeeding women regarding their LTFU in option B+ needs further exploration. We explored reasons for LTFU and motivation to resume treatment among HIV-positive women initiated in option B+ in an Urban setting. A descriptive qualitative study was conducted at three public care and treatment clinics (CTC) (Buguruni health center, Sinza hospital, and Mbagala Rangitatu health center) in Dar es Salaam, Tanzania between February and May 2017. In-depth interviews were conducted with 30 HIV-positive pregnant and breastfeeding women who were lost to follow up in the option B+ regimen. Analysis of data followed content analysis that was performed using NVivo 10 computer-assisted qualitative data analysis software. Eleven women were lost to follow-up and did not resume Option B+, while 19 had resumed treatment. The study indicated a struggle with long term disease amongst HIV-positive pregnant and breastfeeding women initiated in option B+ treatment. The reported reasons contributing to LTFU among these women appeared in three categories. The contribution of LTFU in the first category namely health-related factors included medication side effects and lack of disease symptoms. The second category highlighted the contribution of psychological factors such as loss of hope, fear of medication side effects and HIV-related stigma. The third category underscored the influence of socio-economic statuses such as financial constraints, lack of partner support, family conflicts, non-disclosure of HIV-positive status, and religious beliefs. Motivators to resume treatment after LTFU included support from health care providers and family members, a desire to protect the unborn child from HIV-infection and a need to maintain a healthy status. The study has highlighted the reasons for LTFU and motivation to resume treatment among women initiated in Option B+. Our results provide further evidence on the need for future interventions to focus on these factors in order to improve retention in life-long treatment.
Sections du résumé
BACKGROUND
BACKGROUND
Despite an increased uptake of option B+ treatment among HIV- positive pregnant and breastfeeding women, retaining these women in care is still a major challenge. Previous studies have identified factors associated with loss to follow-up (LTFU) in HIV care, however, the perspectives from HIV-positive pregnant and breastfeeding women regarding their LTFU in option B+ needs further exploration. We explored reasons for LTFU and motivation to resume treatment among HIV-positive women initiated in option B+ in an Urban setting.
METHODS
METHODS
A descriptive qualitative study was conducted at three public care and treatment clinics (CTC) (Buguruni health center, Sinza hospital, and Mbagala Rangitatu health center) in Dar es Salaam, Tanzania between February and May 2017. In-depth interviews were conducted with 30 HIV-positive pregnant and breastfeeding women who were lost to follow up in the option B+ regimen. Analysis of data followed content analysis that was performed using NVivo 10 computer-assisted qualitative data analysis software.
RESULTS
RESULTS
Eleven women were lost to follow-up and did not resume Option B+, while 19 had resumed treatment. The study indicated a struggle with long term disease amongst HIV-positive pregnant and breastfeeding women initiated in option B+ treatment. The reported reasons contributing to LTFU among these women appeared in three categories. The contribution of LTFU in the first category namely health-related factors included medication side effects and lack of disease symptoms. The second category highlighted the contribution of psychological factors such as loss of hope, fear of medication side effects and HIV-related stigma. The third category underscored the influence of socio-economic statuses such as financial constraints, lack of partner support, family conflicts, non-disclosure of HIV-positive status, and religious beliefs. Motivators to resume treatment after LTFU included support from health care providers and family members, a desire to protect the unborn child from HIV-infection and a need to maintain a healthy status.
CONCLUSION
CONCLUSIONS
The study has highlighted the reasons for LTFU and motivation to resume treatment among women initiated in Option B+. Our results provide further evidence on the need for future interventions to focus on these factors in order to improve retention in life-long treatment.
Identifiants
pubmed: 31455306
doi: 10.1186/s12889-019-7518-2
pii: 10.1186/s12889-019-7518-2
pmc: PMC6712622
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1172Subventions
Organisme : NIAID NIH HHS
ID : P30 AI027757
Pays : United States
Organisme : Afya Bora Consortium
ID : U91HA06801B
Références
Nurse Educ Today. 2004 Feb;24(2):105-12
pubmed: 14769454
PLoS Med. 2011 Oct;8(10):e1001111
pubmed: 22039357
J Relig Health. 2013 Dec;52(4):1211-27
pubmed: 22203379
Lancet. 2013 Jan 26;381(9863):269-71
pubmed: 23351797
MMWR Morb Mortal Wkly Rep. 2013 Mar 1;62(8):148-51
pubmed: 23446514
BMC Public Health. 2013 May 07;13:450
pubmed: 23647555
PLoS One. 2013 May 31;8(5):e64979
pubmed: 23741437
J Int AIDS Soc. 2013 Jul 19;16:18588
pubmed: 23870277
Curr Opin HIV AIDS. 2013 Sep;8(5):474-89
pubmed: 23925003
J Adv Pharm Technol Res. 2013 Jul;4(3):134-40
pubmed: 24083200
PLoS One. 2014 Jan 22;9(1):e85310
pubmed: 24465532
AIDS Care. 2014;26(10):1249-57
pubmed: 24666174
Afr J Reprod Health. 2013 Dec;17(4 Spec No):118-29
pubmed: 24689323
J Int Assoc Provid AIDS Care. 2017 Mar/Apr;16(2):140-148
pubmed: 24963087
J Acquir Immune Defic Syndr. 2014 Sep 1;67(1):e12-8
pubmed: 24977376
Trop Med Int Health. 2014 Nov;19(11):1360-6
pubmed: 25087778
PLoS One. 2014 Nov 05;9(11):e111421
pubmed: 25372479
J Acquir Immune Defic Syndr. 2015 Apr 15;68(5):e77-83
pubmed: 25585302
Patient Prefer Adherence. 2015 Mar 05;9:373-80
pubmed: 25784793
AIDS Care. 2016;28(3):334-8
pubmed: 26461806
AIDS Behav. 2016 Oct;20(10):2433-2443
pubmed: 26767534
PLoS One. 2016 Feb 22;11(2):e0149527
pubmed: 26901563
AIDS Care. 2016 Aug;28(8):971-5
pubmed: 26984065
AIDS Care. 2017 Jan;29(1):1-13
pubmed: 27410058
BMC Pregnancy Childbirth. 2017 Mar 21;17(1):94
pubmed: 28320347
PLoS One. 2017 Apr 14;12(4):e0175590
pubmed: 28410374
PLoS One. 2017 Jun 21;12(6):e0179838
pubmed: 28636669
Sex Transm Infect. 2017 Jul;93(Suppl 3):
pubmed: 28736391
Eur J Gen Pract. 2018 Dec;24(1):9-18
pubmed: 29199486